COVID-19 neutralization antibody levels pre- and post-vaccination
VESICULAR STOMATITIS, VIRUS
Neutralization activity was measured with a pseudovirus neutralization assay (pseudotype virus neutralization activity [pVNA] expressed in IU/mL as the assay was calibrated with the National Institute for Biological Standards and Control [NIBSC] standard) and was not detected in the participants before vaccination. After the first vaccination by day 28, neutralization activity was present in all participants sera of the three cohorts (Fig. PTX-COVID19-B vaccine induction of neutralizing antibodies against G614 SARS-CoV-2 and VOCs. Levels of neutralization (IU/mL) of sera from PTX-COVID19-B subjects from day 42 against G614 are shown in Panel A. Levels of neutralization from sera from 28 subjects infected with COVID-19 were also determined. Two tailed t test analysis was performed for titers differences on day 42 between 16 and 40 μg dose and 40 μg dose 100 μg and Levels of neutralization against wild-type D614G and the Alpha (B.1.1.7), Beta (1.351), and Delta (B.1.617.2) VOCs were evaluated at day 42 for all three cohorts (Fig. The magnitude of neutralizing antibody determined by the lentivirus assay and the recombinant Vesicular Stomatitis Virus (rVSV) neutralization assays correlated well (correlation: 0.87 [95% CI 0.80–0.91] 